Tempus Receives FDA Approval for Tumor Only xT CDx, Enabling Migration of its Entire DNA Solid Tumor Portfolio - Business Wire
Business Wire reports on Tempus Receives FDA Approval for Tumor Only xT CDx, Enabling Migration of its Entire DNA Solid Tumor Portfolio in Science & Health.
Take A Coffee NEWS Staff··2 min read
Business Wire reported Tempus Receives FDA Approval for Tumor Only xT CDx, Enabling Migration of its Entire DNA Solid Tumor Portfolio. Take A Coffee NEWS is tracking the story on the Science & Health desk for readers following medicine, public health, research, climate, space, and science policy.
Source
Why it matters
The story belongs in this desk because it may affect readers tracking medicine, public health, research, climate, space, and science policy.